Janux Therapeutics Q3 EPS $(0.25) Beats $(0.47) Estimate, Sales $2.52M Beat $850.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Janux Therapeutics reported Q3 earnings per share (EPS) of $(0.25), beating the analyst consensus estimate of $(0.47) by 46.81%. This is a 37.5% increase over losses from the same period last year. The company also reported quarterly sales of $2.52 million, beating the analyst consensus estimate of $850.00 thousand by 196.12%, a 38.83% increase over sales from the same period last year.
November 07, 2023 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Janux Therapeutics reported better than expected Q3 earnings and sales, which could positively impact the stock in the short term.
Janux Therapeutics reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100